Evidence map›Paper›PMID 35536513›Full record

ArticleParasitology research2022

In silico screening, molecular dynamic simulations, and in vitro activity of selected natural compounds as an inhibitor of Leishmania donovani 3-mercaptopyruvate sulfurtransferase.

Vishnu Kant, Pawan Kumar, Ravi Ranjan, Prakash Kumar, Debabrata Mandal, Saravanan Vijayakumar

Open access · bronzeAbstract read
In one paragraph

Article in Parasitology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Structural analysis of ITS 1 gene ofFrontiers in cellular and infection microbiology · 2026
    Article
  5. Sulfide regulation and catabolism in health and disease.Signal transduction and targeted therapy · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. InhibitingPharmaceuticals (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Vishnu KantDepartment of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, Hajipur, Bihar, India.
Pawan KumarDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, Bihar, India.
Ravi RanjanDivision of Bioinformatics, ICMR-Rajendra Memorial Institute of Medical Sciences, Patna, Bihar, India.
Prakash KumarDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, Bihar, India.
Debabrata MandalDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, Bihar, India. debabrataman@gmail.com.
Saravanan VijayakumarDivision of Bioinformatics, ICMR-Rajendra Memorial Institute of Medical Sciences, Patna, Bihar, India. saravanan.vij@icmr.gov.in.ORCID http://orcid.org/0000-0001-5145-0384
National Institute of Pharmaceutical Education and Research · INRajendra Memorial Research Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Leishmania sp., the enzymes of de novo cysteine biosynthesis pathway require sulfide. Other organisms utilize sulfide through the sulfide reduction pathway, but Leishmania lacks the gene that encodes these enzymes. Hence, the major source of sulfide for Leishmania is believed to be from the action of 3-mercaptopyruvate sulfurtransferase (3MST) on 3-mercapto-pyruvate (3MP). There has been no effort reported in the past to screen inhibitors against L. donovani 3MST (Ld3MST). As a result, this study examines natural compounds that are potent against Ld3MST and validates it by in vitro activity and cytotoxicity tests. Initially, a library of ~ 5000 natural compounds was subjected to molecular docking approach for screening, and the best hit was validated using a long-term molecular dynamic simulation (MD). Among the docking results, quercetine-3-rutinoside (Rutin) was deemed the best hit. The results of the MD indicated that Rutin was highly capable of interacting with the varied active site segments, possibly blocking substrate access. Additionally, promastigotes and amastigotes were tested for Rutin activity and the IC50 was found to be 40.95 and 90.09 μM, respectively. Similarly, the cytotoxicity assay revealed that Rutin was not toxic even at a concentration of 819.00 μM to THP-1 cell lines. Additionally, the Ld3MST was cloned, purified, and evaluated for enzyme activity in the presence of Rutin. Reduction in the enzyme activity (~ 85%) was observed in the presence of ~ 40 μM Rutin. Thus, this study suggests that Rutin may act as a potent inhibitor of Ld3MST. With further in vivo investigations, Rutin could be a small molecule of choice for combating leishmaniasis.

Indexed as

Antiprotozoal AgentsLeishmania donovaniMolecular Docking SimulationMolecular Dynamics SimulationRutinSulfidesSulfurtransferases3-mercaptopyruvate sulphurtransferaseAntiprotozoal AgentsRutinSulfidesSulfurtransferases3MSTDrug targetIC50InhibitorLeishmaniaRutin

Identifiers

PMID35536513
PMCPMC9085559
OpenAlexW4229447505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.